4d Molecular Therapeutics, Inc.

4d Molecular Therapeutics, Inc.

4d Molecular Therapeutics, Inc.

Overview
Date Founded

2013

Headquarters

5858 Horton Street,Suite 455,Emeryville, CA 94608

Type of Company

Public

Employees (Worldwide)

11 - 50

Industries

Biotechnology
Wholesale: Consumer Non-Durables/Sundries

Company Description

4D Molecular Therapeutics, Inc. engages in the design, development, and commercialization of transformative gene therapeutic products for serious unmet medical conditions. It offers products for optalmology, cardiology, and pulmonology. The company was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Contact Data
Trying to get in touch with decision makers at 4d Molecular Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

Chief Strategic Officer & Co-Founder

Chief Financial Officer & Principal Accounting Officer

Chief Operating Officer & Chief Technical Officer

Chief Scientific Officer, Ophthalmology Therapeutic Area Head

Chief Medical Officer

Senior Vice President, Human Resources

Vice President, Discovery & Engineering Co-Founder

Executive Chairman

Chief Business Officer

Board of Directors

Executive Chairman at 4d Molecular Therapeutics, Inc.

Professional at Royalty Pharma Plc

President, Chief Executive Officer & Board Member at ORIC Pharmaceuticals, Inc.

Former President, Chief Executive Officer, Chief Financial Officer & Director at Tracon Pharmaceuticals, Inc.

Co-Founder at 4d Molecular Therapeutics, Inc.

Former Chief Commercial Officer at Pharmacyclics LLC

Former Senior Vice President-Global Human Health Business Development at Schering-Plough Corporation

The Hubbard Howe Junior Distinguished Professor of Biochemical Engineering at University of California, Berkeley - College of Chemistry

Paths to 4d Molecular Therapeutics, Inc.
Potential Connections via
Relationship Science
You
4d Molecular Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Ridgeback Capital Management focuses in investments in healthcare companies.

Details Hidden

Casdin Capital seeks to realize superior long-term adjusted total returns by primarily investing in underappreciated companies with innovative business models in the life sciences and healthcare industry. Their portfolio is generally comprised of small to mid-sized issuers in the following life sciences and healthcare sub-sectors: life sciences instrumentation and information technology, medical testing, drug development and distribution, synthetic biology and agriculture, livestock management and energy production. In addition, the firm also has discretion to invest in certain foreign equity securities if they determine that investments in such securities could generate risk-adjusted returns for their clients. Casdin Capital employs a primary research-intensive approach to investing that is thematically driven and fundamentally based and uses a range of investment strategies, primarily investing in publicly-traded equity or equivalent securities, both long and short, as well as a broad array of other securities.

Details Hidden

BVF Partners pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The firm's investments within the biotechnology sector focus primarily on the securities of companies with market capitalizations of less than $1 billion. BVF may also invest in unregistered securities of public and closely-held private biotechnology companies by directly purchasing from issuers or other shareholders, in privately negotiated transactions, common stock, convertible preferred stock and/or debt instruments with warrants, options and/or similar rights to acquire an equity interest. The firm also pursues a second investment strategy on that invests in equity or equity-linked securities of companies involved in the biotechnology industry and related fields that, as of the time of the acquisition of such securities, have a market capitalization of $350 million to $3 billion.

Recent Transactions
Details Hidden

4d Molecular Therapeutics, Inc. issued USD Common Stock

Details Hidden

4d Molecular Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

4d Molecular Therapeutics, Inc. raised money in a private placement transaction

Insider Transactions
Details Hidden
Transaction Advisors
Escrow Agent

Advised on4d Molecular Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised on4d Molecular Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised on4d Molecular Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised on4d Molecular Therapeutics, Inc. issued USD Common Stock

Associate

Advised on4d Molecular Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised on4d Molecular Therapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Advisor

Former Vice President at Trout Capital LLC

Clients

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Cystic Fibrosis Foundation is a donor-supported non-profit organization which focuses in the search for a cure for cystic fibrosis. The foundation funds cystic fibrosis research. It also supports and accredits a national care center network recognized by the National Institutes f Health as a model of care for a chronic disease. The company was founded in 1955 and is headquartered in Bethesda, MD.

Key Stats and Financials As of 2020
Market Capitalization
$757M
Total Enterprise Value
$829M
Earnings Per Share
$-2.12
Three Year Compounded Annual Growth Rate Of Revenue
32.97%
Debt TEV
0x
TEVNet Income
-14.63x
Enterprise Value / Sales
60.92x
Total Equity
$256M
Total Debt
$0
EBITDAMargin
-405.68%
EBITDA
$-55.2M
Net Profit
$-56.7M
Revenue
$13.6M
Non-Profit Donations & Grants
$5,000 - $10K
2018
Investors
Details Hidden

Ridgeback Capital Management focuses in investments in healthcare companies.

Details Hidden

CureDuchenne Venture invests in companies located in the US. the firm targets the companies operating in the fields of health technology,sector. They provides financing in for early stage capital requirements.

Suppliers
University of California Holding Companies | Oakland, CA

The University is governed by The Regents, which under Article IX, Section 9 of the California Constitution has "full powers of organization and governance" subject only to very specific areas of legislative control. The article states that "the university shall be entirely independent of all political and sectarian influence and kept free therefrom in the appointment of its Regents and in the administration of its affairs." Board Membership Article IX, Section 9 was drafted in 1878 after a decade of political conflict demonstrated the importance of sheltering the university from shifting political winds. The board consists of 26 members: 18 regents are appointed by the governor for 12-year terms One is a student appointed by the Regents to a one-year term Seven are ex officio members -- the Governor, Lieutenant Governor, Speaker of the Assembly, Superintendent of Public Instruction, president and vice president of the Alumni Associations of UC and the UC president. In addition, two faculty members -- the chair and vice chair of the Academic Council -- sit on the board as non-voting members. Board Officers The Governor is officially the president of the Board of Regents; however, in practice the presiding officer of the Regents is the Chairman of the Board, elected from among its body for a one-year term, beginning July 1. The current Chairman is Regent Sherry Lansing. The Vice Chairman is Regent Bruce Varner. The Regents appoints Officers of The Regents: the General Counsel; the Chief Investment Officer; the Secretary and Chief of Staff; and the Chief Compliance and Audit Officer. Former Regents Here is a list of individuals who have served as Regents of the University of California: Former Regents Committees and Meetings The Regents operates through 10 standing committees: Compliance and Audit, Compensation, Educational Policy, Finance, Governance, Grounds and Buildings, Health Services, Investments, Long Range Planning, and Oversight of the Department of Energy Laboratories. The Regents meets six times a year every other month in two-day meetings

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by 4d Molecular Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of 4d Molecular Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and 4d Molecular Therapeutics, Inc..